Strides Shasun Limited and Eris Lifesciences Limited have entered into definitive agreements for sale of Strides’ India branded generics business to Eris for an aggregate cash consideration of Rs. 500 crore.

Strides’ India branded generics business comprises a portfolio of more than 130 brands in the domains of neurology, psychiatry, nutraceuticals, gastro, etc., along with the employees forming part of the business. In terms of the agreement, Eris will acquire the marketing and distribution rights for the said portfolio of products in India, while Strides will retain the global rights for these products.


10 Diagnostic Imaging Trends for 2018

Best of 2017 Medical

 

Digital version